Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences (NYSE: RCUS) reported first overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study for first-line treatment of unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.

At data cutoff March 3, 2025 (n=41, median follow-up 26.4 months), median OS was 26.7 months (90% CI 18.4, NE), median PFS was 12.9 months (90% CI 9.8, 14.6), and confirmed ORR was 59%. The 24-month OS rate was 50.2%. Safety was consistent with anti-PD-1 plus chemotherapy; immune-mediated adverse events occurred in 22% and infusion reactions in 7%. Results will be presented at ESMO 2025 on October 18 and support the Phase 3 STAR-221 program.

Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted inducement equity awards to two new employees on October 9, 2025. The awards include options to purchase a total of 60,300 shares at an exercise price of $15.05 (closing price on October 8, 2025) and restricted stock units to acquire 30,150 shares. The grants were made under the company’s 2020 Inducement Plan using the NYSE "inducement exception" (Rule 303A.08).

The announcement discloses award totals, per‑share exercise price, plan authority, and the date used for pricing.

Arcus Biosciences (NYSE:RCUS) reported Phase 1/1b casdatifan monotherapy data in late-line metastatic clear cell RCC showing a 100mg QD confirmed ORR 35% and pooled confirmed ORR 31% (n=121). Pooled median PFS was 12.2 months with an 18-month PFS of 43%. In the 100mg QD cohort, median PFS was not estimable at ~12.4 months median follow-up. Safety signals included grade ≥3 anemia (pooled 41%) and hypoxia (pooled 11%); treatment discontinuations were ~9%.

Arcus also disclosed five preclinical inflammation and immunology programs with a first clinical study expected in 2026. A webcast is available today at 7:00 AM PT / 10:00 AM ET.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity-based compensation to two new employees. The awards include options to purchase 9,750 shares at an exercise price of $12.39 per share and restricted stock units (RSUs) for 4,900 shares. The grants were made under the company's 2020 Inducement Plan, approved under NYSE's inducement exception Rule 303A.08.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity awards to three new employees. The compensation package includes options to purchase 19,300 shares at $12.19 per share and restricted stock units for 9,700 shares.

These equity awards were granted under the Company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08's "inducement exception".

Arcus Biosciences (NYSE:RCUS) will host an Investor Event on October 6, 2025, at 10:00 AM ET in New York City, offering both in-person and virtual attendance options. The event will showcase new data from the Phase 1b ARC-20 trial of their HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC).

The presentation will feature management team members and key opinion leaders discussing HIF-2a biology and ccRCC treatment. Additionally, Arcus will present its research in autoimmune and inflammatory diseases, with planned new IND filings in 2026 and 2027.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced its participation in three major investor conferences in September 2025:

• Citi's 2025 Biotech Back to School Conference on September 3rd in Boston at 11:15 a.m. ET
• H.C. Wainwright Global Investment Conference on September 9th in New York at 8:00 a.m. ET
• Morgan Stanley Global Healthcare Conference on September 10th in New York at 8:30 a.m. ET

All events will feature fireside chats and one-on-one meetings, with live webcasts available on the company's website.

Arcus Biosciences (NYSE:RCUS) reported Q2 2025 financial results and pipeline updates, highlighting significant progress in its oncology portfolio. The company ended the quarter with $927 million in cash, positioning it well for pipeline advancement. Key developments include the initiation of PEAK-1, a Phase 3 study of casdatifan + cabozantinib in RCC, and eVOLVE-RCC02, a Phase 1b/3 study with AstraZeneca.

Financial highlights include revenues of $160 million (up from $39M in Q2 2024), R&D expenses of $139 million, and break-even net income. The revenue increase was primarily driven by a $143 million cumulative catch-up related to etrumadenant program changes.

Clinical progress includes promising data from ARC-20 study showing 46% confirmed response rate in RCC patients, with additional data readouts expected in fall 2025 and 2026. The company anticipates R&D expenses to decline from Q4 2025 as domvanalimab Phase 3 costs decrease.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity-based compensation to a new employee. The package includes options to purchase 4,200 shares at an exercise price of $9.75 per share and restricted stock units (RSUs) for 2,100 shares. The grants were made under the company's 2020 Inducement Plan, approved under NYSE Rule 303A.08's inducement exception.